Bikman points to the drop in liver fat among people with fatty liver as the part of Lilly's retatrutide results that interests him most.
Recap by typeshit. Post by Benjamin Bikman on X.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
He says shedding tied to GLP-1 drugs usually passes, but can linger, and points to telogen effluvium triggered by fast weight loss.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Loading…